Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pharma Loses €10.2bn, 38,000 Jobs To Counterfeits As “Massive” Track & Trace Obligations Approach

Executive Summary

As a new report reveals that 4.4% of legitimate sales of drugs are lost each year in the EU due to counterfeiting, drug companies are being warned not to underestimate how much work they will need to do to comply with new track and trace rules.

You may also be interested in...



Ireland Chooses "Blueprint" System To Link Into Future EU Product Verification Network

New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.

EU Pharma Has Three Years To Comply With New Safety Feature Rules

The new EU rules on the safety feature to be attached to almost all prescription medicines have finally been published, and once they kick in products will have to carry a 'unique identifier' in the form of a 2D bar code on the pack that will allow its authenticity to be verified1.

New EU Filings

Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS119307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel